Treatment with marine collagen peptides modulates glucose and lipid metabolism in chinese patients with type 2 diabetes mellitus

Applied Physiology, Nutrition and Metabolism

Volumn 35, Issue 6, 2010, Pages 797-804

  Zhu, Cui Feng ^a,b   Li, Guan Zhi ^a   Peng, Hong Bin ^b   Zhang, Fan ^a   Chen, Yun ^a   Li, Yong ^b  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Adipokine; Inflammation; Insulin sensitivity; Marine collagen peptide; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; AUTACOID; C REACTIVE PROTEIN; COLLAGEN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; NITRIC OXIDE; PROTEIN HYDROLYSATE;

AGED; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; FEMALE; FISH; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TIME;

ADIPOKINES; AGED; ANIMALS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHINA; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FEMALE; FISHES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; NITRIC OXIDE; PROTEIN HYDROLYSATES; TIME FACTORS;

EID: 78650271712     PISSN: 17155312     EISSN: 17155320     Source Type: Journal    
DOI: 10.1139/H10-075     Document Type: Article

References (35)

1. Alba, A.C., and Delgado, D.H. 2009. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? Expert Rev. Cardiovasc. Ther. 7(2): 147-157. doi:10.1586/14779072.7.2.147. PMID:19210211.
2. Aneiros, A., and Garateix, A. 2004. Bioactive peptides from marine sources: pharmacological properties and isolation procedures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1): 41-53. doi:10.1016/j.jchromb.2003.11.005. PMID:15025997.
3. Asfandiyarova, N., Kolcheva, N., Ryazantsev, I., and Ryazantsev, V. 2006. Risk factors for stroke in type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 3(1): 57-60. doi:10.3132/dvdr.2006.009. PMID:16784183.
4. Bhatheja, R., and Bhatt, D.L. 2006. Clinical outcomes in metabolic syndrome. J. Cardiovasc. Nurs. 21(4): 298-305. PMID:16823284.
5. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A., and Laakso, M.; STOP-NIDDM Trial Research Group. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 290(4): 486-494. doi:10.1001/jama.290.4.486. PMID:12876091.
6. Consitt, L.A., Bell, J.A., and Houmard, J.A. 2009. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life, 61(1): 47-55. doi:10.1002/iub.142. PMID:18839419.
7. Díez Espino, J. 2010. Diagnosis and management of type 2 diabetes. Aten Primaria, 42(Suppl. 1): 2-8. [In Spanish.] PMID: 21074070.
8. Doi, Y., Kiyohara, Y., Kubo, M., Ninomiya, T., Wakugawa, Y., Yonemoto, K., et al. 2005. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care, 28(10): 2497-2500. doi:10.2337/diacare.28.10.2497. PMID:16186286.
9. Dong, Y., Gao, W., Nan, H., Yu, H., Li, F., Duan, W., et al. 2005. Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao, China. Diabet. Med. 22(10): 1427-1433. doi:10.1111/j.1464-5491.2005.01658.x. PMID:16176207.
10. Freese, R., and Mutanen, M. 1997. a-linolenic acid and marine long-chain n-3 fatty acids differ only slightly in their effects on hemostatic factors in healthy subjects. Am. J. Clin. Nutr. 66(3): 591-598. PMID:9280178.
11. Gelman, L., Feige, J.N., and Desvergne, B. 2007. Molecular basis of selective PPARg modulation for the treatment of type 2 diabetes. Biochim. Biophys. Acta, 1771(8): 1094-1107. PMID: 17459763.
12. Gilpin, V.L. 2010. Review of an article: Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association (AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402. J. Vasc. Nurs. 28(4): 154-155. doi:10.1016/j.jvn.2010.10.002.
13. Guilherme, A., Virbasius, J.V., Puri, V., and Czech, M.P. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9(5): 367-377. doi:10. 1038/nrm2391. PMID:18401346.
14. Havel, P.J. 2002. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13(1): 51-59. doi:10.1097/00041433-200202000-00008. PMID:11790963.
15. Henriksen, E.J., and Jacob, S. 2003. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J. Cell. Physiol. 196(1): 171-179. doi:10.1002/jcp.10294. PMID: 12767053.
16. Henriksen, E.J., Jacob, S., Fogt, D.L., and Dietze, G.J. 1998. Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am. J. Physiol. 275(1 Pt. 2): R40-R45. PMID:9688958.
17. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., et al. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20(6): 1595-1599. PMID: 10845877.
18. Koenig, R.J., Peterson, C.M., Jones, R.L., Saudek, C., Lehrman, M., and Cerami, A. 1976. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N. Engl. J. Med. 295(8): 417-420. doi:10.1056/NEJM197608192950804. PMID:934240.
19. Marion-Letellier, R., De acute;chelotte, P., Iacucci, M., and Ghosh, S. 2009. Dietary modulation of peroxisome proliferator-activated receptor g. Gut, 58(4): 586-593. doi:10.1136/gut.2008.162859. PMID:19017686.
20. Martyn, J.A., Kaneki, M., and Yasuhara, S. 2008. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology, 109(1): 137-148. doi:10.1097/ALN.0b013e3181799d45. PMID:18580184.
21. Meeuwisse-Pasterkamp, S.H., van der Klauw, M.M., and Wolffenbuttel, B.H. 2008. Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Rev. Cardiovasc. Ther. 6(3): 323-341. doi:10.1586/14779072.6.3.323. PMID:18327994.
22. Mizutani, K., Ikeda, K., Ishikado, A., Kawai, Y., and Yamori, Y. 2000. Antihypertensive effect of cattle bone collagen-derived peptides in ovariectomized stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 27(5-6): 416-417. doi:10.1046/j.1440-1681.2000.03243.x. PMID:10831246.
23. Muoio, D.M., and Koves, T.R. 2007. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 a: implications for metabolic disease. Appl. Physiol. Nutr. Metab. 32(5): 874-883. doi:10.1139/H07-083. PMID:18059612.
24. Namjoshi, S., Caccetta, R., and Benson, H.A. 2008. Skin peptides: biological activity and therapeutic opportunities. J. Pharm. Sci. 97(7): 2524-2542. doi:10.1002/jps.21198. PMID:17914716.
25. Oliver, W.R., Jr., Shenk, J.L., Snaith, M.R., Russell, C.S., Plunket, K.D., Bodkin, N.L., et al. 2001. A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98(9): 5306-5311. doi:10.1073/pnas.091021198. PMID:11309497.
26. Pei, X.R., Yang, R.Y., Zhang, Z.F., Xu, Y.J., Han, X.L., Wang, J.B., and Li, Y. 2008. Effects of marine collagen peptide on delaying the skin aging. Zhonghua Yu Fang Yi Xue Za Zhi, 42(4): 235-238. [In Chinese.] PMID:18763632.
27. Pocock, S.J., and Simon, R. 1975. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31(1): 103-115. doi:10.2307/2529712. PMID: 1100130.
28. Qi, W.H., Pan, C.Y., and Lin, S.Y. 2007. A survey of factors influencing prognosis and control rate for patients with hypertension in mainland China. Zhonghua. Xin Xue Guan Bing Za Zhi, 35(5): 457-460. [In Chinese.] PMID:17711690.
29. Rasouli, N., and Kern, P.A. 2008. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 93(11 Suppl. 1): S64-S73. doi:10.1210/jc.2008-1613. PMID: 18987272.
30. Schutta, M.H. 2007. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr. 2(2): 124-130. doi:10.1111/j.1559-4564.2007.06368.x. PMID:17684469.
31. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., et al. 2001. The hormone resistin links obesity to diabetes. Nature, 409(6818): 307-312. doi:10.1038/35053000. PMID:11201732.
32. Uehara, M., Kishikawa, H., Isami, S., Kisanuki, K., Ohkubo, Y., Miyamura, N., et al. 1994. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia, 37(3): 300-307. doi:10.1007/BF00398058. PMID:8174845.
33. Wang, J.B., Xie, Y., Pei, X.R., Yang, R.Y., Zhang, Z.F., and Li, Y. 2008. The lipid-lowering and antioxidative effects of marine collagen peptides. Zhonghua Yu Fang Yi Xue Za Zhi, 42(4): 226-230. [In Chinese.] PMID:18763630.
34. Wilding, J.P. 2007. The importance of free fatty acids in the development of type 2 diabetes. Diabet. Med. 24(9): 934-945. doi:10.1111/j.1464-5491.2007.02186.x. PMID:17725706.
35. Zhang, Z.F., Pei, X.R., Han, X.L., Wang, J.B., Long, Z., Shen, X.Y., and Li, Y. 2008. The study on the immunomodulating effect of marine protein peptides in mice. Zhonghua Yu Fang Yi Xue Za Zhi, 42(4): 221-225. [In Chinese.] PMID:18763629.